These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34180045)

  • 21. Myelodysplastic syndromes: clinical practice guidelines in oncology.
    Greenberg PL; Attar E; Bennett JM; Bloomfield CD; Borate U; De Castro CM; Deeg HJ; Frankfurt O; Gaensler K; Garcia-Manero G; Gore SD; Head D; Komrokji R; Maness LJ; Millenson M; O'Donnell MR; Shami PJ; Stein BL; Stone RM; Thompson JE; Westervelt P; Wheeler B; Shead DA; Naganuma M
    J Natl Compr Canc Netw; 2013 Jul; 11(7):838-74. PubMed ID: 23847220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Updated treatment strategies for myelodysplastic syndromes].
    Ichikawa M
    Rinsho Ketsueki; 2022; 63(6):660-666. PubMed ID: 36184521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of MDS].
    Usuki K
    Rinsho Ketsueki; 2014 Oct; 55(10):1882-92. PubMed ID: 25297752
    [No Abstract]   [Full Text] [Related]  

  • 25. Iron overload in patients with myelodysplastic syndromes: An updated overview.
    Moukalled NM; El Rassi FA; Temraz SN; Taher AT
    Cancer; 2018 Oct; 124(20):3979-3989. PubMed ID: 29905937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving therapies for lower-risk myelodysplastic syndromes.
    Bewersdorf JP; Zeidan AM
    Ann Hematol; 2020 Apr; 99(4):677-692. PubMed ID: 32078008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of myelodysplastic syndromes in elderly patients.
    Sanchez JF
    Adv Ther; 2011 Mar; 28 Suppl 2():1-9. PubMed ID: 21431504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines.
    Mittelman M; Lugassy G; Merkel D; Tamary H; Sarid N; Rachmilewitz E; Hershko C; ;
    Isr Med Assoc J; 2008 May; 10(5):374-6. PubMed ID: 18605364
    [No Abstract]   [Full Text] [Related]  

  • 29. Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform.
    Valent P; Krieger O; Stauder R; Wimazal F; Nösslinger T; Sperr WR; Sill H; Bettelheim P; Pfeilstöcker M
    Eur J Clin Invest; 2008 Mar; 38(3):143-9. PubMed ID: 18218040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myelodysplastic syndromes.
    Scott BL; Deeg HJ
    Annu Rev Med; 2010; 61():345-58. PubMed ID: 20059342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Management of myelodysplastic syndromes].
    Duchmann M; Fenaux P; Cluzeau T
    Bull Cancer; 2015 Nov; 102(11):946-57. PubMed ID: 26410692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JSH Guideline for Tumors of Hematopoietic and Lymphoid Tissues: Leukemia: 6. Myelodysplastic syndromes (MDS).
    Miyazaki Y
    Int J Hematol; 2017 Aug; 106(2):151-159. PubMed ID: 28677111
    [No Abstract]   [Full Text] [Related]  

  • 33. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How to treat MDS without stem cell transplantation.
    Gattermann N
    Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S30-6. PubMed ID: 19857591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Restrictive Versus Liberal Transfusion Strategies in Myelodysplastic Syndrome and Beyond.
    Wilde L; Pan J
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):758-762. PubMed ID: 31678078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline.
    Wells RA; Leber B; Buckstein R; Lipton JH; Hasegawa W; Grewal K; Yee K; Olney HJ; Larratt L; Vickars L; Tinmouth A
    Leuk Res; 2008 Sep; 32(9):1338-53. PubMed ID: 18405971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standard therapy for patients with myelodysplastic syndromes.
    Al-Ameri A; Cherry M; Garcia-Manero G; Quintás-Cardama A
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):303-13. PubMed ID: 21816368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
    Greenberg PL; Stone RM; Al-Kali A; Barta SK; Bejar R; Bennett JM; Carraway H; De Castro CM; Deeg HJ; DeZern AE; Fathi AT; Frankfurt O; Gaensler K; Garcia-Manero G; Griffiths EA; Head D; Horsfall R; Johnson RA; Juckett M; Klimek VM; Komrokji R; Kujawski LA; Maness LJ; O'Donnell MR; Pollyea DA; Shami PJ; Stein BL; Walker AR; Westervelt P; Zeidan A; Shead DA; Smith C
    J Natl Compr Canc Netw; 2017 Jan; 15(1):60-87. PubMed ID: 28040720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pathophysiology, diagnosis and treatment of anemia].
    Ozawa K
    Nihon Rinsho; 2008 Mar; 66(3):423-8. PubMed ID: 18326312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.